From these preliminary observations, it is tempting to suggest that interventions aimed at enriching the gut microbiota with bacteria associated with NAFLD resolution (e.g., Bacteroides or Akkermansia), as well as with FXR agonists, could help to achieve maximum rates of NAFLD resolution in BS patients. This evidence concerns the gene NR1H4 and metabolic dysfunction-associated steatotic liver disease.